ClinicalTrials.gg
CompletedNCT03525600Updated Jun 18, 2023Results posted

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

A Phase 3 interventional study of APL-2 and APL-2 in Geographic Atrophy, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 141 sites in 15 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
621
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
9th of 107
621 · median 98
Started
2018
with 7 others
Phase 3
15 of 131
2 open now
Registered
53rd of 131
by date
Lead sponsor
8 of 131
Apellis Pharmaceuticals, Inc.

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 9th largest by enrollment of the 107 interventional ones that give a count, is one of 8 that started in 2018, is one of 15 in phase 3, and was the 53rd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.

03

Conditions studied

  • Geographic Atrophy

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with the worst visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be selected as the study eye.

Ocular- specific inclusion criteria apply to the study eye only, unless otherwise specified.

  • Age ≥ 60 years.
  • Normal Luminance best corrected visual acuity of 24 letters or better using Early Treatment Diabetic Retinopathy Study (ETDRS) charts (approximately 20/320 Snellen equivalent).
  • Clinical diagnosis of GA of the macula secondary to AMD as determined by the Investigator and confirmed by the Reading Center.
  • The GA lesion must meet the following criteria as determined by the central reading center's assessment of Fundus Autofluorescence (FAF) imaging at screening:

    • Total GA area must be ≥ 2.5 and ≤ 17.5 mm2 (1 and 7 disk areas [DA] respectively)
    • If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm2 (0.5 DA), with the overall aggregate area of GA as specified above in 4a.
    • The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.
    • Presence of any pattern of hyperautofluorescence in the junctional zone of GA. Absence of hyperautofluorescence (i.e. pattern = none) is exclusionary.
  • Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images as determined by the Investigator.
  • Female subjects must be:

    • Women of non- (WONCBP), or
    • Women of child-bearing potential (WOCBP) with a negative serum pregnancy test at screening and must agree to use protocol defined methods of for the duration of the study and refrain from breastfeeding for the duration of the study.
  • Males with female partners of child-bearing potential must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study.
  • Willing and able to give and to comply with the study procedures and assessments.

Exclusion criteria

Exclusion Criteria:

Ocular specific exclusion criteria apply to the study eye only, unless otherwise specified.

  • GA secondary to a condition other than AMD such as Stargardt disease, cone rod dystrophy or toxic maculopathies like plaquenil maculopathy in either eye.
  • Spherical equivalent of the refractive error demonstrating > 6 diopters of myopia or an axial length >26 mm.
  • Any history or active choroidal neovascularization (CNV), associated with AMD or any other cause, including any evidence of retinal pigment epithelium rips or evidence of neovascularization anywhere based on SD-OCT imaging and/or fluorescein angiography as assessed by the Reading Center.
  • Presence of an active ocular disease that in the opinion of the Investigator compromises or confounds visual function, including but not limited to, uveitis, other macular diseases (e.g. epiretinal membrane (ERM), full thickness macular hole or uncontrolled glaucoma/ocular hypertension. Benign conditions in the opinion of the investigator such as peripheral retina dystrophy are not exclusionary).
  • Intraocular surgery (including lens replacement surgery) within 3 months prior to randomization.
  • History of laser therapy in the macular region.
  • Aphakia or absence of the posterior capsule. Note: YAG laser posterior capsulotomy for posterior capsule opacification done at least 60 days prior to screening is not exclusionary.
  • Any ocular condition other than GA secondary to AMD that may require surgery or medical intervention during the study period or, in the opinion of the Investigator, could compromise visual function during the study period.
  • Any to IVT injection including current ocular or periocular infection.
  • History of prior intravitreal injection.
  • Prior participation in another interventional clinical study for intravitreal therapies in either eye (including subjects receiving sham).
  • Prior participation in another interventional clinical study for geographic atrophy in either eye including oral medication and placebo.
  • Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Note: clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary.
  • Medical or psychiatric conditions that, in the opinion of the investigator, make consistent follow-up over the 24-month treatment period unlikely, or would make the subject an unsafe study candidate.
  • Any screening laboratory value (hematology, serum chemistry or urinalysis) that in the opinion of the Investigator is clinically significant and not suitable for study participation.
  • Known to fluorescein sodium for injection or hypersensitivity to APL-2 or any of the in APL-2 solution.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
621 participants (actual)

Study arms

  • Experimental
    APL-2 15mg 0.1 mL monthly for 24 months

    A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month

    Drug: APL-2

  • Experimental
    APL-2 15mg 0.1 mL EOM for 24 months

    A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month

    Drug: APL-2

  • Experimental
    Sham Procedure Monthly for 24 months

    Sham Procedure for 24 months

    Other: Sham Procedure

  • Experimental
    Sham Procedure Every Other Month for 24 months

    Sham Procedure every other month for 24 months

    Other: Sham Procedure

Interventions

  • DrugAPL-2

    Complement (C3) Inhibitor

  • DrugAPL-2

    Complement (C3) Inhibitor

  • OtherSham Procedure

    Subjects will receive a Sham procedure every month

  • OtherSham Procedure

    Subjects will receive a Sham procedure every other month

06

What researchers measure

Primary outcomes

  1. Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12

    The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure (MMRM) model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 12

Secondary outcomes

  1. LS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 24

    The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

  2. Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24

    The mean change in GA lesion area through Month 24 was measured by assuming a piecewise linear trend in time with knots by FAF images at Months 6, 12, and 18 and was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: From Baseline (screening) through Month 24

  3. LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24

    The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNREAD) or Radner Reading Charts user manuals, with no adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute (wpm) was implemented. Maximum reading speed was calculated as the mean of the 3 highest non-zero reading speeds (or 2, or 1 value, as available), except when all wpm were calculated as 0 then the maximum reading speed was calculated as 0. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

  4. LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24

    The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD subjects. It had 1 total index score. For each FRI Index reading activity performed in the past 7 days, subjects were asked about the extent to which they required assistance beyond eyeglasses/contact lenses, including the use of low-vision aids, adjustments in the activity, or help from another subject. Mean FRI Index scores ranged from 1 (unable to do independently) to 4 (totally independent), with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI; disease worsening. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

  5. LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24

    The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was \>19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A positive change in the value indicated improvement in visual acuity. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (screening) and Month 24

07

Results

Posted Jun 18, 2023

Participant flow

This Phase III, randomized, double-masked, sham injection-controlled study was conducted in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at 122 sites in 14 countries between 31 Aug 2018 and 20 Jun 2022.

Participant flow — Overall Study
MilestonePegcetacoplan MonthlyPegcetacoplan EOMSham MonthlySham EOM
Started206208102105
Completed1471617883
Not completed59472422
Withdrew: Adverse event9653
Withdrew: Lost to follow-up2440
Withdrew: Physician decision1020
Withdrew: Consent withdrawal3620613
Withdrew: Death7643
Withdrew: Due to coronavirus disease-2019 (covid-19) impact41033
Withdrew: Other0100

Outcome measures

PrimaryLeast Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12

The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure (MMRM) model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 12
Reported as:
Least squares mean · mm^2
Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12
mm^2Pegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 121.7344 ± 0.079241.7563 ± 0.074461.9640 ± 0.09592
Statistical analysis
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0615 · Ls mean difference: -0.2296 · 95% CI -0.4703 to 0.0111
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0854 · Ls mean difference: -0.2077 · 95% CI -0.4444 to 0.0290
SecondaryLS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 24

The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · mm^2
LS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 24
mm^2Pegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 243.2275 ± 0.124573.3395 ± 0.130343.9726 ± 0.16820
Statistical analysis
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0004 · Ls mean difference: -0.7451 · 95% CI -1.1539 to -0.3362
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0030 · Ls mean difference: -0.6331 · 95% CI -1.0508 to -0.2153
SecondaryMean Change in Total Area of GA Lesions in the Study Eye Through Month 24

The mean change in GA lesion area through Month 24 was measured by assuming a piecewise linear trend in time with knots by FAF images at Months 6, 12, and 18 and was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
From Baseline (screening) through Month 24
Reported as:
Least squares mean · mm^2
Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24
mm^2Pegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
From Baseline to Month 60.9075 ± 0.047550.8829 ± 0.046600.9622 ± 0.04983
From Month 6 to Month 120.8409 ± 0.051280.8473 ± 0.050861.0132 ± 0.05998
From Month 12 to Month 180.9033 ± 0.049170.8803 ± 0.051051.0483 ± 0.05574
From Month 18 to Month 240.6262 ± 0.068090.6946 ± 0.052560.9794 ± 0.05469
From Baseline to Month 243.2780 ± 0.125253.3051 ± 0.128714.0031 ± 0.16880
Statistical analysis
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.4282 · Mean difference: -0.0547 · 95% CI -0.1899 to 0.0806
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.2457 · Mean difference: -0.0793 · 95% CI -0.2131 to 0.0546
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0292 · Mean difference: -0.1722 · 95% CI -0.3270 to -0.0174
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0352 · Mean difference: -0.1659 · 95% CI -0.3202 to -0.0115
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0514 · Mean difference: -0.1450 · 95% CI -0.2909 to 0.0009
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0265 · Mean difference: -0.1680 · 95% CI -0.3164 to -0.0196
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = <0.0001 · Mean difference: -0.3532 · 95% CI -0.5245 to -0.1819
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0002 · Mean difference: -0.2848 · 95% CI -0.4336 to -0.1361
  • Pegcetacoplan Monthly vs Sham Pooled · MMRM model · p = 0.0006 · Mean difference: -0.7251 · 95% CI -1.1373 to -0.3129
  • Pegcetacoplan EOM vs Sham Pooled · MMRM model · p = 0.0010 · Mean difference: -0.6980 · 95% CI -1.1142 to -0.2817
SecondaryLS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24

The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNREAD) or Radner Reading Charts user manuals, with no adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute (wpm) was implemented. Maximum reading speed was calculated as the mean of the 3 highest non-zero reading speeds (or 2, or 1 value, as available), except when all wpm were calculated as 0 then the maximum reading speed was calculated as 0. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · wpm
LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24
wpmPegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24-22.897 ± 4.1171-25.532 ± 2.7676-22.355 ± 2.9341
SecondaryLS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24

The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD subjects. It had 1 total index score. For each FRI Index reading activity performed in the past 7 days, subjects were asked about the extent to which they required assistance beyond eyeglasses/contact lenses, including the use of low-vision aids, adjustments in the activity, or help from another subject. Mean FRI Index scores ranged from 1 (unable to do independently) to 4 (totally independent), with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI; disease worsening. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · scores on a scale
LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24
scores on a scalePegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24-0.408 ± 0.0570-0.371 ± 0.0562-0.360 ± 0.0601
SecondaryLS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24

The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was \>19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A positive change in the value indicated improvement in visual acuity. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (screening) and Month 24
Reported as:
Least squares mean · ETDRS letter score
LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24
ETDRS letter scorePegcetacoplan MonthlyPegcetacoplan EOMSham Pooled
LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24-8.126 ± 1.0182-8.947 ± 1.0322-6.217 ± 1.0167

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were reported from first study drug administration (Day 1) up to the last visit or early termination visit, 30 days after the last study drug administration for the monthly treatment groups and 60 days after the last study drug administration for the EOM treatment groups, a maximum of 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegcetacoplan Monthly: Ocular Study Eye0/206 (0%)4/206 (1.9%)113/206 (54.9%)
Pegcetacoplan EOM: Ocular Study Eye0/208 (0%)2/208 (1%)82/208 (39.4%)
Sham Pooled: Ocular Study Eye0/206 (0%)2/206 (1%)61/206 (29.6%)
Pegcetacoplan Monthly: Ocular Fellow Eye0/206 (0%)1/206 (0.5%)35/206 (17%)
Pegcetacoplan EOM: Ocular Fellow Eye0/208 (0%)1/208 (0.5%)34/208 (16.3%)
Sham Pooled: Ocular Fellow Eye0/206 (0%)0/206 (0%)29/206 (14.1%)
Pegcetacoplan Monthly: Non-ocular8/206 (3.9%)61/206 (29.6%)90/206 (43.7%)
Pegcetacoplan EOM: Non-ocular6/208 (2.9%)47/208 (22.6%)70/208 (33.7%)
Sham Pooled: Non-ocular8/206 (3.9%)53/206 (25.7%)101/206 (49%)
Most frequent serious events
Showing 10 of 174
Most frequent serious events
EventPegcetacoplan Monthly: Ocular Study EyePegcetacoplan EOM: Ocular Study EyeSham Pooled: Ocular Study EyePegcetacoplan Monthly: Ocular Fellow EyePegcetacoplan EOM: Ocular Fellow EyeSham Pooled: Ocular Fellow EyePegcetacoplan Monthly: Non-ocularPegcetacoplan EOM: Non-ocularSham Pooled: Non-ocular
PneumoniaInfections and infestations0/2060/2080/2060/2060/2080/2062/2067/2083/206
Cerebrovascular accidentNervous system disorders0/2060/2080/2060/2060/2080/2065/2062/2083/206
SyncopeNervous system disorders0/2060/2080/2060/2060/2080/2064/2062/2081/206
SepsisInfections and infestations0/2060/2080/2060/2060/2080/2060/2064/2080/206
Atrial fibrillationCardiac disorders0/2060/2080/2060/2060/2080/2063/2062/2080/206
Cardiac failure congestiveCardiac disorders0/2060/2080/2060/2060/2080/2063/2061/2081/206
Urinary tract infectionInfections and infestations0/2060/2080/2060/2060/2080/2062/2062/2083/206
FallInjury, poisoning and procedural complications0/2060/2080/2060/2060/2080/2063/2063/2081/206
COVID-19Infections and infestations0/2060/2080/2060/2060/2080/2062/2063/2081/206
VitritisEye disorders2/2060/2080/2060/2060/2080/2060/2060/2080/206
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPegcetacoplan Monthly: Ocular Study EyePegcetacoplan EOM: Ocular Study EyeSham Pooled: Ocular Study EyePegcetacoplan Monthly: Ocular Fellow EyePegcetacoplan EOM: Ocular Fellow EyeSham Pooled: Ocular Fellow EyePegcetacoplan Monthly: Non-ocularPegcetacoplan EOM: Non-ocularSham Pooled: Non-ocular
Vitreous floatersEye disorders24/20610/2083/2063/2061/2084/2060/2060/2080/206
Neovascular age-related macular degenerationEye disorders21/20610/2085/2067/20611/2088/2060/2060/2080/206
Urinary tract infectionInfections and infestations0/2060/2080/2060/2060/2080/20617/20613/20821/206
FallInjury, poisoning and procedural complications0/2060/2080/2060/2060/2080/20610/20615/20821/206
HypertensionVascular disorders0/2060/2080/2060/2060/2080/20617/20616/20815/206
Visual acuity reducedEye disorders16/2066/20810/20610/2066/2084/2060/2060/2080/206
Conjunctival haemorrhageEye disorders12/20615/2085/2061/2064/2081/2060/2060/2080/206
Retinal haemorrhageEye disorders9/20615/2088/2062/2064/2087/2060/2060/2080/206
ArthralgiaMusculoskeletal and connective tissue disorders0/2060/2080/2060/2060/2080/20610/2066/20814/206
Vitreous detachmentEye disorders8/20614/2086/2068/2064/2083/2060/2060/2080/206

Baseline characteristics

The Intent-to-treat (ITT) analysis set consisted of all subjects assigned to treatment.

Age, Continuous
Age, Continuous(years)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Mean78.8 ± 6.9179.2 ± 7.0678.5 ± 7.2478.8 ± 7.07
Sex: Female, Male
Sex: Female, Male(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Female121126132379
Male858275242
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
White192192200584
Not reported1211629
Black or African American1102
Asian0101
Multiple0101
Unknown1214
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Hispanic or Latino32372998
Not Hispanic or Latino163155172490
Not Reported1012628
Unknown1405
Region of Enrollment
Region of Enrollment(Participants)Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
United States146126128400
Argentina18241860
France1214733
Brazil9131032
United Kingdom561021
Germany341118
Poland27615
Czechia27514
Australia3148
Canada2147
Israel0426
Italy2103
Spain1023
New Zealand1001
GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye
GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye(Millimeter square (mm^2))Pegcetacoplan MonthlyPegcetacoplan EOMSham PooledTotal
Mean8.3606 ± 4.168928.2076 ± 3.912138.2572 ± 4.218648.2749 ± 4.09557
08

Study locations

141 sites
  • Retinal Research Institute
    Phoenix, Arizona 85014, United States
  • Associated Retina Consultants, Ltd
    Phoenix, Arizona 85020, United States
  • Retina Institute of California dba Acuity Eye Grp
    Arcadia, California 91007, United States
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • Retina Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • The Retina Partners
    Encino, California 91436, United States
  • The Gavin Herbert Eye Institute/UC Irvine
    Irvine, California 92697, United States
  • Northern California Retina Vitreous Associates
    Mountain View, California 94040, United States
  • Retina Institute of California Medical Group
    Palm Desert, California 92260, United States
  • Byers Eye Institute at Standford, Stanford School of Medicine
    Palo Alto, California 94303, United States
  • Retina Consultants San Diego
    Poway, California 92064, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • California Retina Consultants
    Santa Barbara, California 93103, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
  • Danbury Eye Physicians & Surgeons, P.C. - Danbury
    Danbury, Connecticut 06810, United States
  • New England Retina Associates
    Hamden, Connecticut 06518, United States
  • Retina Group of New England,PC
    Waterford, Connecticut 06385, United States
  • Florida Eye Microsurgical Institute, Inc.
    Boynton Beach, Florida 33426, United States
  • Pinnacle Research Institute
    Fort Lauderdale, Florida 33309, United States
  • Retina Health Center
    Fort Myers, Florida 33907, United States
  • Bascom Palmer Eye Institute
    Palm Beach Gardens, Florida 33418, United States
  • Eye Associates of Pinellas
    Pinellas Park, Florida 33782, United States
  • East Florida Eye Institute
    Stuart, Florida 34994, United States
  • Southern Vitreoretinal Associates
    Tallahassee, Florida 32308, United States
  • Retina Associates of Florida
    Tampa, Florida 33609, United States
  • University of South Florida (USF) Eye Institute
    Tampa, Florida 33612, United States
  • Southeast Retina Center, PC
    Augusta, Georgia 30909, United States
  • Georgia Retina
    Marietta, Georgia 30060, United States
  • Midwest Eye Institute
    Indianapolis, Indiana 46290, United States
  • Sabates Eye Center
    Leawood, Kansas 66211, United States
  • Elman Retina Group, PA
    Baltimore, Maryland 21236, United States
  • Cumberland Valley Retina Consultants, PC
    Hagerstown, Maryland 21740, United States
  • Mid Atlantic Retina Specialists
    Hagerstown, Maryland 21740, United States
  • Retina Specialists
    Towson, Maryland 21204, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
  • New England Retina Consultants, PC
    Springfield, Massachusetts 01107, United States
  • Associated Retinal Consultants, P.C
    Grand Rapids, Michigan 49546, United States
  • Retina Specialists of Michigan / Foundation for Vision
    Grand Rapids, Michigan 49546, United States
  • Retina Consultants of Michigan
    Southfield, Michigan 48034, United States
  • Associated Retinal Consultants PC
    Traverse City, Michigan 49686, United States
  • Sierra Eye Associates
    Reno, Nevada 89503, United States
  • Retina Associates of New Jersey (NJ Retina)
    Teaneck, New Jersey 07666, United States
  • Long Island Vitreoretinal Consultants
    Great Neck, New York 11021, United States
  • Vitreous Retina Macula Consultants of NY
    New York, New York 10022, United States
  • Western Carolina Retinal Associates
    Asheville, North Carolina 28803, United States
  • Charlotte Eye Ear Nose and Throat Associates, PS
    Charlotte, North Carolina 28210, United States
  • Graystone Eye
    Hickory, North Carolina 28602, United States
  • Retina Associates of Cleveland, Inc.
    Cleveland, Ohio 44122, United States
  • Retina Associates of Cleveland, Inc
    Cleveland, Ohio 44122, United States
  • Retina Associates of Cleveland
    Cleveland, Ohio 44130, United States
  • Cleveland Clinic, Cole Eye Institute
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Columbus, Ohio 43212, United States
  • Retina Associates of Cleveland, Inc.
    Youngstown, Ohio 44505, United States
  • Retina Northwest, PC
    Portland, Oregon 97221, United States
  • Eye Health Northwest
    Portland, Oregon 97225, United States
  • Mid Atlantic Retina
    Philadelphia, Pennsylvania 19006, United States
  • Black Hills Regional Eye Institute
    Rapid City, South Dakota 57701, United States
  • Tennessee Retina, PC
    Nashville, Tennessee 37203, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Southwest Retina Specialists
    Amarillo, Texas 79106, United States
  • Retina Consultants of Austin (Retina Research Center)
    Austin, Texas 78705, United States
  • Retina Consultants of Houston, PA
    Houston, Texas 77030, United States
  • Valley Retina Institute, PA
    McAllen, Texas 78503, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
  • Retinal Consultants of San Antonio
    San Antonio, Texas 78240, United States
  • Retina Consultants of Houston
    The Woodlands, Texas 77384, United States
  • Retina Associates of Utah, PC
    Murray, Utah 84107, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • The Retina Group of Washington
    Fairfax, Virginia 22031, United States
  • Virginia Retina Center
    Warrenton, Virginia 20186, United States
  • Vitreoretinal Associates of Washington
    Bellevue, Washington 98004, United States
  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
  • University of Wisconsin
    Madison, Wisconsin 53715, United States
  • Fundacion Zambrano
    Buenos Aires, Capital Federal C1023 AAQ, Argentina
  • Microcirugia Ocular
    Rosario, Corrientes 2000, Argentina
  • Grupo Laser Vision
    Rosario, Santa Fe S2000 AZH, Argentina
  • Organizacion Medica de investigacion
    Buenos Aires, C1015 ABO, Argentina
  • Centro Oftalmologico Dr Charles
    Buenos Aires, C1116ABA, Argentina
  • Diagnostico Ocular
    Buenos Aires, C1425BGE, Argentina
  • Centro Privado de Ojos Romagosa SA
    Córdoba, X5000AAJ, Argentina
  • Instituto Oftalmologico de Cordoba
    Córdoba, X5000III, Argentina
  • Oftar Mendoza SRL
    Mendoza, 5500, Argentina
  • Oftalmologos Especialistas
    Rosario, 1288, Argentina
  • Sydney Retina
    Sydney, New South Wales 2000, Australia
  • Centre for Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Retina and Eye Consultants
    Hurstville, NSW 2220, Australia
  • Clinica Ocular Oftalmologia LTDA
    Vitória, Espirito Santo 29055-45, Brazil
  • Clinica Oftalmologica Sao Lucas
    Osasco, Sao Paulo 06010-130, Brazil
  • IPEPO - Instituto Da Visao
    São Paulo, Vila Clementino 04038-032, Brazil
  • Instituto da Visão - Hospital de Olhos Ltda
    Belo Horizonte, 32150-274, Brazil
  • Hospital De Clinicas De Porto Alegre
    Porto Alegre, 90036-903, Brazil
  • UNIFESP - Federal University
    São Paulo, 04021-001, Brazil
  • Ivey Eye Institute
    London, Ontario N6A, Canada
  • University of Ottawa Eye Institute
    Ottawa, Ontario K1H 8L6, Canada
  • DRY AMD Clinic - St. Michael's Hospital
    Toronto, Ontario M5C 1R6, Canada
  • Retina Centre of Ottawa
    Ottawa, K2B 7E9, Canada
  • Fakultní nemocnice Ostrava
    Ostrava-Poruba, 708 52, Czechia
  • OFTEX Eye Clinic
    Pardubice, 53002, Czechia
  • AXON Clinical, S.R.O.
    Praha, 150 00, Czechia
  • University Hospital Kralovske Vinochrady
    Vinohrady, 100 34, Czechia

Showing the first 100 of 141 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jun 2021, 33 months.

Results were first posted in Jun 2023, 1 year 11 months after primary completion. A results delay was requested in Jun 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2018
First posted
May 15, 2018
StartActual
Aug 31, 2018
Primary completionActual
Jun 21, 2021
CompletionActual
Jun 20, 2022
Results delay requested
Jun 20, 2022
Results first posted
Jun 18, 2023
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03525600
Responsible party
Sponsor
First posted
May 15, 2018
Start date
Aug 31, 2018
Primary completion
Jun 21, 2021
Completion
Jun 20, 2022
Results posted
Jun 18, 2023
Last update
Jun 18, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion